Dry eye disease and microbial keratitis: Is there a connection?

Ocular Surface

Volumn 11, Issue 2, 2013, Pages 75-92

  Narayanan, Srihari ^a   Redfern, Rachel L ^b   Miller, William L ^b   Nichols, Kelly K ^b   Mcdermott, Alison M ^b  

^a University of Incarnate Word   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Antimicrobial peptides; Conjunctiva; Contact lens; Cornea; Cyclosporine; Dry eye; Infection; Innate immunity; Ocular surface inflammation; Tears

Indexed keywords

AZITHROMYCIN; BENZALKONIUM CHLORIDE; BETA DEFENSIN 1; BETA DEFENSIN 2; BETA DEFENSIN 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DOXYCYCLINE; LACTOFERRIN; LIPOCALIN; LOTEPREDNOL; LYSOZYME; MINOCYCLINE; MUCIN; PATTERN RECOGNITION RECEPTOR; PHOSPHOLIPASE A2; SECRETORY IMMUNOGLOBULIN; TETRACYCLINE; TOBRAMYCIN;

ARTICLE; BACTERIAL KERATITIS; BLEPHARITIS; CONTACT LENS; DRY EYE; HUMAN; INFECTION RISK; INNATE IMMUNITY; MEIBOMIAN GLAND; NONHUMAN; OCULAR SURFACE DISEASE; PATHOGEN LOAD; ROSACEA;

EID: 84876577553     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtos.2012.12.002     Document Type: Review

References (267)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:75-92
2. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93-107
3. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eye syndrome. Adv Exp Med Biol 2002;506:989-98
4. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008;14:S102-6
5. Abetz L, Rajagopalan K, Mertzanis P, et al. Development and validation of the impact of dry eye on everyday life (IDEEL) questionnaire, a patient-reported outcomes (PRO) measure for the assessment of the burden of dry eye on patients. Health Qual Life Outcomes 2011;9:111
6. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol 2010;21:310-6
7. Pouyeh B, Viteri E, Feuer W, et al. Impact of ocular surface symptoms on quality of life in a United States Veterans Affairs population. Am J Ophthalmol 2012;153:1061-6
8. Clegg JP, Guest JF, Lehman A, Smith AF. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol 2006;13:263-74
9. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004;23:751-61
10. Lemp MA. Advances in understanding and managing dry eye disease. Am J Ophthalmol 2008;146:350-6
11. Perry HD, Donnenfeld ED. Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 2004;15:299-304
12. Calonge M, Enriquez-de-Salamanca A, Diebold Y, et al. Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010;18:244-53
13. Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol 2008;71:89-95
14. Stern ME, Siemasko KF, Gao J, et al. Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. Ocul Surf 2005;3:S161-4
15. Pflugfelder SC, Solomon A, Dursun D, Li DQ. Dry eye and delayed tear clearance: "a call to arms". Adv Exp Med Biol 2002;506:739-43
16. Corrales RM, Narayanan S, Fernandez I, et al. Ocular mucin gene expression levels as biomarkers for the diagnosis of dry eye syndrome. Invest Ophthalmol Vis Sci 2011;52:8363-9
17. Narayanan S, Corrales RM, Farley W, et al. Interleukin-1 receptor-1- deficient mice show attenuated production of ocular surface inflammatory cytokines in experimental dry eye. Cornea 2008;27:811-7
18. Kimura K. [Molecular mechanism of the disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-alpha, a proinflammatory cytokine]. Nihon Ganka Gakkai Zasshi 2010;114:935-43. Japanese
19. Klocke J, Barcia RN, Heimer S, et al. Spontaneous bacterial keratitis in CD36 knockout mice. Invest Ophthalmol Vis Sci 2011;52:256-63
20. Cavanagh HD, Robertson DM, Petroll WM, Jester JV. Castroviejo Lecture 2009: 40 years in search of the perfect contact lens. Cornea 2010;29:1075-85
21. Medzhitov R, Janeway CA, Jr. An ancient system of host defense. Curr Opin Immunol 1998;10:12-5
22. Medzhitov R, Janeway CA, Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998;10:351-3
23. Weissman BA, Giese MJ, Mondino BJ. An introduction to ocular immunology. Optom Clin 1994;3:1-22
24. Dudley DJ. The immune system in health and disease. Baillieres Clin Obstet Gynaecol 1992;6:393-416
25. Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immunemediated ocular surface disorder. Arch Ophthalmol 2012;130:90-100
26. Pflugfelder SC, de Paiva CS, Li DQ, Stern ME. Epithelial-immune cell interaction in dry eye. Cornea 2008;(27 Suppl 1):S9-11
27. Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:179-93
28. Yanoff M, Duker JS, Augsburger JJ. Ophthalmology. St. Louis, MO, Mosby, 2004: xxii, 1652 pp
29. Kwong MS, Evans DJ, Ni M, et al. Human tear fluid protects against Pseudomonas aeruginosa keratitis in a murine experimental model. Infect Immun 2007;75:2325-32
30. Bialasiewicz AA, Shenoy R, Al-Muniri A, Thakral A. [Diseases of the adnexa in the tropics: amnion membrane transplantation for noninfectious trachoma-associated corneal ulcers]. Ophthalmologe 2006;103:940-4. German
31. Ormerod LD, Collin HB, Dohlman CH, et al. Paraproteinemic crystalline keratopathy. Ophthalmology 1988;95:202-12
32. Narayanan S, Miller WL, Prager TC, et al. The diagnosis and characteristics of moderate dry eye in non-contact lens wearers. Eye Contact Lens 2005;31:96-104
33. Morgan PB, Maldonado-Codina C. Corneal staining: do we really understand what we are seeing? Cont Lens Anterior Eye 2009;32: 48-54
34. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. Am J Pathol 2005;166:61-71
35. Tabery HM. Dual appearance of fluorescein staining in vivo of diseased human corneal epithelium. A non-contact photomicrographic study. Br J Ophthalmol 1992;76:43-4
36. Mokhtarzadeh M, Casey R, Glasgow BJ. Fluorescein punctate staining traced to superficial corneal epithelial cells by impression cytology and confocal microscopy. Invest Ophthalmol Vis Sci 2011;52:2127-35
37. Fleiszig SM, Evans DJ. Pathogenesis of contact lens-associated microbial keratitis. Optom Vis Sci 2010;87:225-32
38. Tam C, LeDue J, Mun JJ, et al. 3D quantitative imaging of unprocessed live tissue reveals epithelial defense against bacterial adhesion and subsequent traversal requires MyD88. PLoS One 2011;6:e24008
39. Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:108-52
40. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011;52:1922-9
41. Jhanji V, Constantinou M, Taylor HR, Vajpayee RB. Microbiological and clinical profiles of patients with microbial keratitis residing in nursing homes. Br J Ophthalmol 2009;93:1639-42
42. Van Der Beek MT, Bernards AT, Lapid-Gortzak R. Mycobacterium chelonae keratitis in a patient with Sjogren's syndrome. Eur J Ophthalmol 2008;18:294-6
43. Boiko EV, Chernysh VF, Pozniak AL, Ageev VS. [To the role of Chlamydia infection in the development of dry eye]. Vestn Oftalmol 2008;124:16-9. Russian
44. Krasny J, Hruba D, Netukova M, et al. [Chlamydia pneumoniae in the etiology of the keratoconjunctivitis sicca in adult patients (a pilot study)]. Cesk Slov Oftalmol 2009;65:102-6. Czech
45. Petroutsos G, Paschides CA, Kitsos G, et al. [Sterile corneal ulcers in dry eye. II. Treatment, complications and course]. J Fr Ophtalmol 1992;15:106-11. French
46. Petroutsos G, Paschides CA, Kitsos G, et al. [Sterile corneal ulcers in dry eye. Incidence and factors of occurrence]. J Fr Ophtalmol 1992;15:103-5. French
47. Hemady R, Chu W, Foster CS. Keratoconjunctivitis sicca and corneal ulcers. Cornea 1990;9:170-3
48. Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogren's syndrome. Arch Ophthalmol 1980;98:89-94
49. Vivino FB, Minerva P, Huang CH, Orlin SE. Corneal melt as the initial presentation of primary Sjogren's syndrome. J Rheumatol 2001;28: 379-82
50. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol 2003;87:834-8
51. Keay L, Edwards K, Naduvilath T, et al. Microbial keratitis predisposing factors and morbidity. Ophthalmology 2006;113:109-16
52. Green M, Apel A, Stapleton F. A longitudinal study of trends in keratitis in Australia. Cornea 2008;27:33-9
53. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea 2008;27:22-7
54. Heimer S, Mun JJ, Stern M, et al. Ocular resistance to Pseudomonas aeruginosa infection in a murine model of dry eye disease. Invest Ophthalmol Vis Sci 2010: E-Abstract 3897
55. Poggio EC, Glynn RJ, Schein OD, et al. The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. N Engl J Med 1989;321:779-83
56. Schein OD, Glynn RJ, Poggio EC, et al. The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group. N Engl J Med 1989;321:773-8
57. Stapleton F, Dart JK, Minassian D. Risk factors with contact lens related suppurative keratitis. CLAO J 1993;19:204-10
58. Stapleton F, Dart JK, Seal DV, Matheson M. Epidemiology of Pseudomonas aeruginosa keratitis in contact lens wearers. Epidemiol Infect 1995;114:395-402
59. Stapleton F. Contact lens-related microbial keratitis: what can epidemiologic studies tell us? Eye Contact Lens 2003;29:S85-9. discussion S115-8, S92-4
60. MacRae S, Herman C, Stulting RD, et al. Corneal ulcer and adverse reaction rates in premarket contact lens studies. Am J Ophthalmol 1991;111:457-65
61. Dart JK, Radford CF, Minassian D, et al. Risk factors for microbial keratitis with contemporary contact lenses: a case-control study. Ophthalmology 2008;115:1647-54. 54 e1-3
62. Keay L, Stapleton F, Schein O. Epidemiology of contact lens-related inflammation and microbial keratitis: a 20-year perspective. Eye Contact Lens 2007;33:346-53. discussion 62-3
63. Alarcon I, Tam C, Mun JJ, et al. Factors impacting corneal epithelial barrier function against Pseudomonas aeruginosa traversal. Invest Ophthalmol Vis Sci 2011;52:1368-77
64. Fleiszig SM. The Glenn A. Fry award lecture 2005. The pathogenesis of contact lens-related keratitis. Optom Vis Sci 2006;83:866-73
65. Fleiszig SM, Evans DJ, Do N, et al. Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infect Immun 1997;65:2861-7
66. Tam C, Mun JJ, Evans DJ, Fleiszig SM. The impact of inoculation parameters on the pathogenesis of contact lens-related infectious keratitis. Invest Ophthalmol Vis Sci 2010;51:3100-6
67. Efron N, Morgan PB. Rethinking contact lens associated keratitis. Clin Exp Optom 2006;89:280-98
68. Sack RA, Beaton A, Sathe S, et al. Towards a closed eye model of the pre-ocular tear layer. Prog Retin Eye Res 2000;19:649-68
69. Sack RA, Sathe S, Hackworth LA, et al. The effect of eye closure on protein and complement deposition on Group IV hydrogel contact lenses: relationship to tear flow dynamics. Curr Eye Res 1996;15: 1092-100
70. Sack RA, Tan KO, Tan A. Diurnal tear cycle: evidence for a nocturnal inflammatory constitutive tear fluid. Invest Ophthalmol Vis Sci 1992;33:626-40
71. Thakur A, Willcox MD, Stapleton F. The proinflammatory cytokines and arachidonic acid metabolites in human overnight tears: homeostatic mechanisms. J Clin Immunol 1998;18:61-70
72. Imayasu M, Moriyama T, Ichijima H, et al. The effects of daily wear of rigid gas permeable contact lenses treated with contact lens care solutions containing preservatives on the rabbit cornea. CLAO J 1994;20:183-8
73. Imayasu M, Petroll WM, Jester JV, et al. The relation between contact lens oxygen transmissibility and binding of Pseudomonas aeruginosa to the cornea after overnight wear. Ophthalmology 1994;101:371-88
74. Jalbert I, Sweeney DF, Stapleton F. The effect of long-term wear of soft lenses of low and high oxygen transmissibility on the corneal epithelium. Eye (Lond) 2009;23:1282-7
75. Ladage PM, Yamamoto K, Ren DH, et al. Effects of rigid and soft contact lens daily wear on corneal epithelium, tear lactate dehydrogenase, and bacterial binding to exfoliated epithelial cells. Ophthalmology 2001;108:1279-88
76. O'Leary DJ, Madgewick R, Wallace J, Ang J. Size and number of epithelial cells washed from the cornea after contact lens wear. Optom Vis Sci 1998;75:692-6
77. Ren DH, Petroll WM, Jester JV, et al. Short-term hypoxia downregulates epithelial cell desquamation in vivo, but does not increase Pseudomonas aeruginosa adherence to exfoliated human corneal epithelial cells. CLAO J 1999;25:73-9
78. Yamamoto N, Petroll MW, Cavanagh HD, Jester JV. Internalization of Pseudomonas aeruginosa is mediated by lipid rafts in contact lenswearing rabbit and cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci 2005;46:1348-55
79. Yamamoto N, Petroll MW, Jester JV, Cavanagh HD. Regulation of Pseudomonas aeruginosa internalization after contact lens wear in vivo and in serum-free culture by ocular surface cells. Invest Ophthalmol Vis Sci 2006;47:3430-40
80. Fleiszig SM, Efron N, Pier GB. Extended contact lens wear enhances Pseudomonas aeruginosa adherence to human corneal epithelium. Invest Ophthalmol Vis Sci 1992;33:2908-16
81. Lin MC, Polse KA. Hypoxia, overnight wear, and tear stagnation effects on the corneal epithelium: data and proposed model. Eye Contact Lens 2007;33:378-81. discussion 82
82. Sweeney D. Silicone hydrogels: the rebirth of continuous wear contact lenses. Oxford, Boston, Butterworth Heinemann, 2000: xiv, 279 pp
83. Begley CG, Caffery B, Nichols KK, Chalmers R. Responses of contact lens wearers to a dry eye survey. Optom Vis Sci 2000;77:40-6
84. Begley CG, Chalmers RL, Mitchell GL, et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea 2001;20:610-8
85. Doughty MJ, Fonn D, Richter D, et al. A patient questionnaire approach to estimating the prevalence of dry eye symptoms in patients presenting to optometric practices across Canada. Optom Vis Sci 1997;74:624-31
86. Nichols JJ, Mitchell GL, Nichols KK, et al. The performance of the contact lens dry eye questionnaire as a screening survey for contact lens-related dry eye. Cornea 2002;21:469-75
87. Nichols JJ, Ziegler C, Mitchell GL, Nichols KK. Self-reported dry eye disease across refractive modalities. Invest Ophthalmol Vis Sci 2005;46:1911-4
88. Schafer J, Mitchell GL, Chalmers RL, et al. The stability of dryness symptoms after refitting with silicone hydrogel contact lenses over 3 years. Eye Contact Lens 2007;33:247-52
89. Pritchard N, Fonn D. Dehydration, lens movement and dryness ratings of hydrogel contact lenses. Ophthalmic Physiol Opt 1995;15: 281-6
90. Richdale K, Sinnott LT, Skadahl E, Nichols JJ. Frequency of and factors associated with contact lens dissatisfaction and discontinuation. Cornea 2007;26:168-74
91. Schlanger JL. A study of contact lens failures. J Am Optom Assoc 1993;64:220-4
92. Young G, Veys J, Pritchard N, Coleman S. A multi-centre study of lapsed contact lens wearers. Ophthalmic Physiol Opt 2002;22: 516-27
93. Nichols JJ, Sinnott LT. Tear film, contact lens, and patient-related factors associated with contact lens-related dry eye. Invest Ophthalmol Vis Sci 2006;47:1319-28
94. Fonn D, Situ P, Simpson T. Hydrogel lens dehydration and subjective comfort and dryness ratings in symptomatic and asymptomatic contact lens wearers. Optom Vis Sci 1999;76:700-4
95. Chalmers R, Long B, Dillehay S, Begley C. Improving contact-lens related dryness symptoms with silicone hydrogel lenses. Optom Vis Sci 2008;85:778-84
96. Dillehay SM, Miller MB. Performance of Lotrafilcon B silicone hydrogel contact lenses in experienced low-Dk/t daily lens wearers. Eye Contact Lens 2007;33:272-7
97. Kojima T, Matsumoto Y, Ibrahim OM, et al. Effect of controlled adverse chamber environment exposure on tear functions in silicon hydrogel and hydrogel soft contact lens wearers. Invest Ophthalmol Vis Sci 2011;52:8811-7
98. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007;26:1195-9
99. Takahide K, Parker PM, Wu M, et al. Use of fluid-ventilated, gaspermeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007;13:1016-21
100. Cole N, Bao S, Stapleton F, et al. Pseudomonas aeruginosa keratitis in IL-6-deficient mice. Int Arch Allergy Immunol 2003;130:165-72
101. Dogru M, Ward SK, Wakamatsu T, et al. The effects of 2 week senofilcon-A silicone hydrogel contact lens daily wear on tear functions and ocular surface health status. Cont Lens Anterior Eye 2011;34:77-82
102. Nichols JJ, Green-Church KB. Mass spectrometry-based proteomic analyses in contact lens-related dry eye. Cornea 2009;28:1109-17
103. Chalmers RL, Keay L, Long B, et al. Risk factors for contact lens complications in US clinical practices. Optom Vis Sci 2010;87:725-35
104. Stapleton F, Carnt N. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye (Lond) 2012;26:185-93
105. Stapleton F, Edwards K, Keay L, et al. Risk factors for moderate and severe microbial keratitis in daily wear contact lens users. Ophthalmology 2012;119:1516-21
106. Miller D, Iovieno A. The role of microbial flora on the ocular surface. Curr Opin Allergy Clin Immunol 2009;9:466-70
107. Dong Q, Brulc JM, Iovieno A, et al. Diversity of bacteria at healthy human conjunctiva. Invest Ophthalmol Vis Sci 2011;52:5408-13
108. Willamson J, Doig WM, Forrester JV, et al. Studies of the viral flora in keratoconjunctivitis sicca. Br J Ophthalmol 1975;59:45-6
109. Robert PY, Traccard I, Adenis JP, et al. Multiplex detection of herpesviruses in tear fluid using the "stair primers" PCR method: prospective study of 93 patients. J Med Virol 2002;66:506-11
110. Albietz JM, Lenton LM. Effect of antibacterial honey on the ocular flora in tear deficiency and meibomian gland disease. Cornea 2006;25:1012-9
111. Graham JE, Moore JE, Jiru X, et al. Ocular pathogen or commensal: a PCR-based study of surface bacterial flora in normal and dry eyes. Invest Ophthalmol Vis Sci 2007;48:5616-23
112. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol 1984;68:524-8
113. Groden LR, Murphy B, Rodnite J, Genvert GI. Lid flora in blepharitis. Cornea 1991;10:50-3
114. Seal DV, McGill JI, Mackie IA, et al. Bacteriology and tear protein profiles of the dry eye. Br J Ophthalmol 1986;70:122-5
115. Shine WE, Silvany R, McCulley JP. Relation of cholesterol-stimulated Staphylococcus aureus growth to chronic blepharitis. Invest Ophthalmol Vis Sci 1993;34:2291-6
116. Sharma S. Diagnosis of external ocular infections: microbiological processing and interpretation. Br J Ophthalmol 2000;84:229
117. Ta CN, Chang RT, Singh K, et al. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology 2003;110:1946-51
118. Cuello OH, Caorlin MJ, Reviglio VE, et al. Rhodococcus globerulus keratitis after laser in situ keratomileusis. J Cataract Refract Surg 2002;28:2235-7
119. Fleiszig SM, Evans DJ. Contact lens infections: can they ever be eradicated? Eye Contact Lens 2003;29:S67-71. discussion S83-4, S192-4
120. Hori Y, Maeda N, Sakamoto M, et al. Bacteriologic profile of the conjunctiva in the patients with dry eye. Am J Ophthalmol 2008;146: 729-34
121. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? Br J Dermatol 2008;158:442-55
122. Berry M, Corfield AP, Harris A, Khan-Lim D. Functional processing of ocular mucins. Adv Exp Med Biol 2002;506:283-8
123. Berry M, Pult H, Purslow C, Murphy PJ. Mucins and ocular signs in symptomatic and asymptomatic contact lens wear. Optom Vis Sci 2008;85:E930-8
124. Aronowicz JD, Shine WE, Oral D, et al. Short term oral minocycline treatment of meibomianitis. Br J Ophthalmol 2006;90:856-60
125. Iovieno A, Lambiase A, Micera A, et al. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol 2009;19:708-16
126. Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40 mg doxycycline in a slow release form. J Dtsch Dermatol Ges 2011;9:904-7
127. Shine WE, McCulley JP, Pandya AG. Minocycline effect on meibomian gland lipids in meibomianitis patients. Exp Eye Res 2003;76: 417-20
128. Ta CN, Shine WE, McCulley JP, et al. Effects of minocycline on the ocular flora of patients with acne rosacea or seborrheic blepharitis. Cornea 2003;22:545-8
129. Williamson J, Gordon AM, Wood R, et al. Fungal flora of the conjunctival sac in health and disease. Influence of topical and systemic steroids. Br J Ophthalmol 1968;52:127-37
130. Yan Z, Young AL, Hua H, Xu Y. Multiple oral Candida infections in patients with Sjogren's syndrome e prevalence and clinical and drug susceptibility profiles. J Rheumatol 2011;38:2428-31
131. Koh S, Maeda N, Soma T, et al. Development of methicillin-resistant Staphylococcus aureus keratitis in a dry eye patient with a therapeutic contact lens. Eye Contact Lens 2012;38:200-2
132. Gregory MS. Innate immune systems and the eye. In: Dartt DA, Besharse J, Dana MR, eds. Encyclopedia of the eye. Elsevier, 2010. p. 439-45
133. McDermott AM. Defense mechanisms of tears and ocular surface. In: Dartt DA, Besharse J, Dana MR, eds. Encyclopedia of the eye. Elsevier, 2010. p. 1-8
134. Pearlman E, Johnson A, Adhikary G, et al. Toll-like receptors at the ocular surface. Ocul Surf 2008;6:108-16
135. Redfern RL, McDermott AM. Toll-like receptors in ocular surface disease. Exp Eye Res 2010;90:679-87
136. Barabino S, Rolando M, Bonini S, et al. Tollelike receptor (TLR) 2 and TLR4 expression in dry eye: (abstract). Invest Ophthalmol Vis Sci 2006: E-Abstract 5594
137. Redfern RL, Patel N, Hanlon S, et al. Toll-like receptor expression and activation in mice with experimental dry eye. Invest Ophthalmol Vis Sci 2013: in press
138. Lee HS, Hattori T, Park EY, et al. Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease. Invest Ophthalmol Vis Sci 2012;53:5632-40
139. Janssen PT, van Bijsterveld OP. Origin and biosynthesis of human tear fluid proteins. Invest Ophthalmol Vis Sci 1983;24:623-30
140. Bezkorovainy A, Topouzian N. The effect of metal chelators and other metabolic inhibitors on the growth of Bifidobacterium bifidus var. Pennsylvanicus. Clin Biochem 1981;14:135-41
141. Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2010;1:440-64
142. Garcia-Montoya IA, Cendon TS, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin a multiple bioactive protein: An overview. Biochim Biophys Acta 2012;182:226-36
143. Albert DM, Jakobiec FA. Principles and practice of ophthalmology. ed 2. Philadelphia, WB Saunders, 2000
144. Aho HJ, Saari KM, Kallajoki M, Nevalainen TJ. Synthesis of group II phospholipase A2 and lysozyme in lacrimal glands. Invest Ophthalmol Vis Sci 1996;37:1826-32
145. Boukes RJ, Boonstra A, Breebaart AC, et al. Analysis of human tear protein profiles using high performance liquid chromatography (HPLC). Doc Ophthalmol 1987;67:105-13
146. McCollum CJ, Foulks GN, Bodner B, et al. Rapid assay of lactoferrin in keratoconjunctivitis sicca. Cornea 1994;13:505-8
147. Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol 2003;136:291-9
148. Zhou L, Beuerman RW, Chan CM, et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res 2009;8:4889-905
149. Grus FH, Podust VN, Bruns K, et al. SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest Ophthalmol Vis Sci 2005;46:863-76
150. Caffery B, Joyce E, Boone A, et al. Tear lipocalin and lysozyme in Sjogren and non-Sjogren dry eye. Optom Vis Sci 2008;85:661-7
151. Versura P, Nanni P, Bavelloni A, et al. Tear proteomics in evaporative dry eye disease. Eye (Lond) 2010;24:1396-402
152. Mantis NJ, Rol N, Corthesy B. Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut. Mucosal Immunol 2011;4: 603-11
153. Franklin RM, Remus LE. Conjunctival-associated lymphoid tissue: evidence for a role in the secretory immune system. Invest Ophthalmol Vis Sci 1984;25:181-7
154. Wieczorek R, Jakobiec FA, Sacks EH, Knowles DM. The immunoarchitecture of the normal human lacrimal gland. Relevancy for understanding pathologic conditions. Ophthalmology 1988;95:100-9
155. Wehmeyer A, Das PK, Swaak T, et al. Sjogren syndrome: comparative studies in local ocular and serum immunoglobulin concentrations with special reference to secretory IgA. Int Ophthalmol 1991;15:147-51
156. Lan J, Willcox MD, Jackson GD. Effect of tear-specific immunoglobulin A on the adhesion of Pseudomonas aeruginosa I to contact lenses. Aust N Z J Ophthalmol 1999;27:218-20
157. Willcox MD, Lan J. Secretory immunoglobulin A in tears:functions and changes during contact lens wear. Clin Exp Optom 1999;82:1-3
158. Pearce DJ, Demirci G, Willcox MD. Secretory IgA epitopes in basal tears of extended-wear soft contact lens wearers and in non-lens wearers. Aust N Z J Ophthalmol 1999;27:221-3
159. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu Rev Biochem 2008;77:495-520
160. Buckland AG, Wilton DC. The antibacterial properties of secreted phospholipases A(2). Biochim Biophys Acta 2000;1488:71-82
161. Nevalainen TJ, Graham GG, Scott KF. Antibacterial actions of secreted phospholipases A2. Review. Biochim Biophys Acta 2008;1781:1-9
162. Qu XD, Lehrer RI. Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect Immun 1998;66:2791-7
163. Aho V, Nevalainen T, Saari M. Group IIA phospholipase A2 content of tears in patients with keratoconjunctivitis sicca. Graefes Arch Clin Experl Ophthalmol 2002;240:521-3
164. Chen D, Wei Y, Li X, et al. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised. Exp Eye Res 2009;88:880-8
165. Wei Y, Epstein SP, Fukuoka S, et al. sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model. Invest Ophthalmol Vis Sci 2011;52:4780-8
166. Debailleul V, Laine A, Huet G, et al. Human mucin genes MUC2, MUC3, MUC4, MUC5AC, MUC5B, and MUC6 express stable and extremely large mRNAs and exhibit a variable length polymorphism. An improved method to analyze large mRNAs. J Biol Chem 1998;273: 881-90
167. Argueso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci 2002;43:1004-11
168. Argueso P, Spurr-Michaud S, Russo CL, et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci 2003;44:2487-95
169. Berry M, Ellingham RB, Corfield AP. Polydispersity of normal human conjunctival mucins. Invest Ophthalmol Vis Sci 1996;37:2559-71
170. Corrales RM, Calonge M, Herreras JM, et al. Human epithelium from conjunctival impression cytology expresses MUC7 mucin gene. Cornea 2003;22:665-71
171. Corrales RM, Galarreta DJ, Herreras JM, et al. [Normal human conjunctival epithelium expresses MUC13, MUC15, MUC16 and MUC17 mucin genes]. Arch Soc Esp Oftalmol 2003;78:375-81. Spanish
172. Diebold Y, Corrales RM, Calonge M, et al. Human conjunctival epithelium in culture: a tool to assay new therapeutic strategies for dry eye. Adv Exp Med Biol 2002;506:307-11
173. Inatomi T, Spurr-Michaud S, Tisdale AS, Gipson IK. Human corneal and conjunctival epithelia express MUC1 mucin. Invest Ophthalmol Vis Sci 1995;36:1818-27
174. Inatomi T, Spurr-Michaud S, Tisdale AS, et al. Expression of secretory mucin genes by human conjunctival epithelia. Invest Ophthalmol Vis Sci 1996;37:1684-92
175. Jumblatt MM, McKenzie RW, Jumblatt JE. MUC5AC mucin is a component of the human precorneal tear film. Invest Ophthalmol Vis Sci 1999;40:43-9
176. Jumblatt MM, McKenzie RW, Steele PS, et al. MUC7 expression in the human lacrimal gland and conjunctiva. Cornea 2003;22:41-5
177. McKenzie RW, Jumblatt JE, Jumblatt MM. Quantification of MUC2 and MUC5AC transcripts in human conjunctiva. Invest Ophthalmol Vis Sci 2000;41:703-8
178. Pflugfelder SC, Liu Z, Monroy D, et al. Detection of sialomucin complex (MUC4) in human ocular surface epithelium and tear fluid. Invest Ophthalmol Vis Sci 2000;41:1316-26
179. Govindarajan B, Gipson IK. Membrane-tethered mucins have multiple functions on the ocular surface. Exp Eye Res 2010;90:655-63
180. Blalock TD, Spurr-Michaud SJ, Tisdale AS, et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci 2007;48:4509-18
181. Imbert Y, Darling DS, Jumblatt MM, et al. MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls. Exp Eye Res 2006;83:493-501
182. Blalock TD, Spurr-Michaud SJ, Tisdale AS, Gipson IK. Release of membrane-associated mucins from ocular surface epithelia. Invest Ophthalmol Vis Sci 2008;49:1864-71
183. Enriquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 2010;16:862-73
184. Caffery B, Heynen ML, Joyce E, et al. MUC1 expression in Sjogren's syndrome, KCS, and control subjects. Mol Vis 2010;16:1720-7
185. Yu DF, Chen Y, Han JM, et al. MUC19 expression in human ocular surface and lacrimal gland and its alteration in Sjogren syndrome patients. Exp Eye Res 2008;86:403-11
186. Gipson IK. Distribution of mucins at the ocular surface. Exp Eye Res 2004;78:379-88
187. Danjo Y, Watanabe H, Tisdale AS, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci 1998;39: 2602-9
188. Mantelli F, Argueso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol 2008;8:477-83
189. Lievin-Le Moal V, Servin AL. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin Microbiol Rev 2006;19:315-37
190. McDermott AM. The role of antimicrobial peptides at the ocular surface. Ophthalmic Res 2009;41:60-75
191. Huang LC, Jean D, Proske RJ, et al. Ocular surface expression and in vitro activity of antimicrobial peptides. Curr Eye Res 2007;32:595-609
192. Huang LC, Redfern RL, Narayanan S, et al. In vitro activity of human beta-defensin 2 against Pseudomonas aeruginosa in the presence of tear fluid. Antimicrob Agents Chemother 2007;51:3853-60
193. McDermott AM. Cationic antimicrobial peptides. A future therapeutic option? Arch Soc Esp Oftalmol 2007;82:467-70
194. McDermott AM. Defensins and other antimicrobial peptides at the ocular surface. Ocul Surf 2004;2:229-47
195. Narayanan S, Manning J, Proske R, McDermott AM. Effect of hyperosmolality on beta-defensin gene expression by human corneal epithelial cells. Cornea 2006;25:1063-8
196. McDermott AM, Rich D, Cullor J, et al. The in vitro activity of selected defensins against an isolate of Pseudomonas in the presence of human tears. Br J Ophthalmol 2006;90:609-11
197. Gordon YJ, Huang LC, Romanowski EG, et al. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 2005;30:385-94
198. Narayanan S, Miller WL, McDermott AM. Expression of human betadefensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci 2003;44:3795-801
199. McDermott AM, Redfern RL, Zhang B, et al. Defensin expression by the cornea: multiple signalling pathways mediate IL-1beta stimulation of hBD-2 expression by human corneal epithelial cells. Invest Ophthalmol Vis Sci 2003;44:1859-65
200. McDermott AM, Redfern RL, Zhang B. Human beta-defensin 2 is up-regulated during re-epithelialization of the cornea. Curr Eye Res 2001;22:64-7
201. Narayanan S, Miller WL, McDermott AM. Expression of human b-Defensins in conjunctival epithelium: relevance to dry eye disease. Invest Ophthalmol Vis Sci 2003;44:3795-801
202. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidin-deficient (Cnlp -/- ) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007;48:4498-508
203. Haynes RJ, Tighe PJ, Dua HS. Antimicrobial defensin peptides of the human ocular surface. Br J Ophthalmol 1999;83:737-41
204. Garreis F, Schlorf T, Worlitzsch D, et al. Roles of human betadefensins in innate immune defense at the ocular surface: arming and alarming corneal and conjunctival epithelial cells. Histochem Cell Biol 2010;134:59-73
205. Huang LC, Petkova TD, Reins RY, et al. Multifunctional roles of human cathelicidin (LL-37) at the ocular surface. Invest Ophthalmol Vis Sci 2006;47:2369-80
206. Augustin DK, Heimer SR, Tam C, et al. Role of defensins in corneal epithelial barrier function against Pseudomonas aeruginosa traversal. Infect Immun 2011;79:595-605
207. Wu M, McClellan SA, Barrett RP, et al. Beta-defensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis. J Immunol 2009;183:8054-60
208. Kawasaki S, Kawamoto S, Yokoi N, et al. Up-regulated gene expression in the conjunctival epithelium of patients with Sjogren's syndrome. Exp Eye Res 2003;77:17-26
209. Kaneda Y, Yamaai T, Mizukawa N, et al. Localization of antimicrobial peptides human beta-defensins in minor salivary glands with Sjogren's syndrome. Eur J Oral Sci 2009;117:506-10
210. Abedin A, Mohammed I, Hopkinson A, Dua HS. A novel antimicrobial peptide on the ocular surface shows decreased expression in inflammation and infection. Invest Ophthalmol Vis Sci 2008;49:28-33
211. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010;135:1-11
212. Howl J, Jones S. Bioactive peptides. Boca Raton, CRC Press, 2009: xv, 479 pp, 8 pp of plates
213. Kolar SS, McDermott AM. Role of host-defence peptides in eye diseases. Cell Mol Life Sci 2011;68:2201-13
214. McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye. Surv Ophthalmol 2012;57:293-316
215. Radfar L, Shea Y, Fischer SH, et al. Fungal load and candidiasis in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003;96:283-7
216. Labbe A, Alalwani H, Van Went C, et al. The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease. Invest Ophthalmol Vis Sci 2012;53:4926-31
217. McMonnies CW. Blink efficiency: a neglected area of ocular surface disease management? Invest Ophthalmol Vis Sci 2011;52:4484
218. Alarcon I, Kwan L, Yu C, et al. Role of the corneal epithelial basement membrane in ocular defense against Pseudomonas aeruginosa. Infect Immun 2009;77:3264-71
219. Luo L, Li DQ, Corrales RM, Pflugfelder SC. Hyperosmolar saline is a proinflammatory stress on the mouse ocular surface. Eye Contact Lens 2005;31:186-93
220. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci 2004;45:4293-301
221. Ni M, Evans DJ, Hawgood S, et al. Surfactant protein D is present in human tear fluid and the cornea and inhibits epithelial cell invasion by Pseudomonas aeruginosa. Infect Immun 2005;73:2147-56
222. Maltseva IA, Fleiszig SM, Evans DJ, et al. Exposure of human corneal epithelial cells to contact lenses in vitro suppresses the upregulation of human beta-defensin-2 in response to antigens of Pseudomonas aeruginosa. Exp Eye Res 2007;85:142-53
223. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Work-Shop (2007). Ocul Surf 2007;5:163-78
224. Narayanan S. Which drop for dry eye? Review of Optometry 2009;146:4
225. Ryan G, Jr, Fain JM, Lovelace C, Gelotte KM. Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system. BMC Ophthalmol 2011;11:8
226. Hyon JY, Eser I, O'Brien TP. Kill rates of preserved and preservativefree topical 8-methoxy fluoroquinolones against various strains of Staphylococcus. J Cataract Refract Surg 2009;35:1609-13
227. Kowalski RP, Kowalski BR, Romanowski EG, et al. The in vitro impact of moxifloxacin and gatifloxacin concentration (0.5% vs 0.3%) and the addition of benzalkonium chloride on antibacterial efficacy. Am J Ophthalmol 2006;142:730-5
228. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992;99:873-8
229. Kimura K, Teranishi S, Kawamoto K, Nishida T. Protection of human corneal epithelial cells from hypoxia-induced disruption of barrier function by hepatocyte growth factor. Exp Eye Res 2010;90:337-43
230. Huang LC, Jean D, McDermott AM. Effect of preservative-free artificial tears on the antimicrobial activity of human beta-defensin-2 and cathelicidin LL-37 in vitro. Eye Contact Lens 2005;31:34-8
231. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42
232. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9
233. Clipstone NA, Fiorentino DF, Crabtree GR. Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes. J Biol Chem 1994;269:26431-7
234. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707-47
235. Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 2000;19:492-6
236. Brignole F, Pisella PJ, De Saint Jean M, et al. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001;42:90-5
237. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 2000;118:1489-96
238. Guzey M, Satici A, Karaman SK, et al. The effect of topical cyclosporine A treatment on corneal thickness in patients with trachomatous dry eye. Clin Exp Optom 2009;92:349-55
239. Hara Y, Shiraishi A, Kobayashi T, et al. Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections. Mol Vis 2009;15: 937-48
240. Sheppard JD, Wertheimer ML, Scoper SV. Modalities to decrease stromal herpes simplex keratitis reactivation rates. Arch Ophthalmol 2009;127:852-6
241. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-74
242. Salisbury MA, Kaswan RL, Brown J. Microorganisms isolated from the corneal surface before and during topical cyclosporine treatment in dogs with keratoconjunctivitis sicca. Am J Vet Res 1995;56:880-4
243. Bell NP, Karp CL, Alfonso EC, et al. Effects of methylprednisolone and cyclosporine A on fungal growth in vitro. Cornea 1999;18:306-13
244. Onyewu C, Afshari NA, Heitman J. Calcineurin promotes infection of the cornea by Candida albicans and can be targeted to enhance fluconazole therapy. Antimicrob Agents Chemother 2006;50:3963-5
245. Djalilian AR, Nagineni CN, Mahesh SP, et al. Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea 2006;25:709-14
246. Flueckiger F, Kodjikian L, Halberstadt M, et al. An ex-vivo, wholeglobe porcine model of corneoepithelial wound healing tested using immunomodulatory drugs. J Ocul Pharmacol Ther 2005;21:367-75
247. Garweg JG, Wegmann-Burns M, Goldblum D. Effects of daunorubicin, mitomycin C, azathioprine and cyclosporin A on human retinal pigmented epithelial, corneal endothelial and conjunctival cell lines. Graefes Arch Clin Exp Ophthalmol 2006;244:382-9
248. Terai K, Sano Y, Kawasaki S, et al. Effects of dexamethasone and cyclosporin A on human beta-defensin in corneal epithelial cells. Exp Eye Res 2004;79:175-80
249. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993;(38 Suppl):115-32
250. Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, pairedcomparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;(38 Suppl):133-40
251. Ilyas H, Slonim CB, Braswell GR, et al. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens 2004;30:10-3
252. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992;9:1275-8
253. Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam 2012;2012: 789623
254. Suto C, Morinaga M, Yagi T, et al. Conjunctival sac bacterial flora isolated prior to cataract surgery. Infect Drug Resist 2012;5:37-41
255. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996;40:343-67
256. Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001;42:2283-92
257. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res 2006;83:526-35
258. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989;30:1569-75
259. Abdel-Khalek LM, Williamson J, Lee WR. Morphological changes in the human conjunctival epithelium. II. In keratoconjunctivitis sicca. Br J Ophthalmol 1978;62:800-6
260. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res 2006;82:588-96
261. Hoeprich PD, Warshauer DM. Entry of four tetracyclines into saliva and tears. Antimicrob Agents Chemother 1974;5:330-6
262. Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob Agents Chemother 2003;47:3630-3
263. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci 1991;32:2970-5
264. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomiangland dysfunction: acomparative clinical and spectroscopic pilot study. Cornea 2013;32:44-53
265. Foulks GN, Borchman D, Yappert M, et al. Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea 2010;29:781-8
266. Luchs J. Azithromycin in DuraSite for the treatment of blepharitis. Clin Ophthalmol 2010;4:681-8
267. Nichols JJ, Bickle KM, Zink RC, et al. Safety and efficacy of topical azithromycin ophthalmic solution 1.0% in the treatment of contact lens-related dry eye. Eye Contact Lens 2012;38:73-9